Bruker (NASDAQ: BRKR) reported Q2 EPS of $0.44, $0.06 better than the analyst estimate of $0.38. Revenue for the quarter came in at $570.8 million versus the consensus estimate of $538.29 million.

Frank H. Laukien, President and CEO of Bruker, commented: “Bruker’s revenues, margins and earnings grew strongly in the first half of 2021, as markets rebounded and demand for our high-performance scientific instruments, life science research and diagnostic solutions accelerated. Our teams executed well across our core businesses as well as our Project Accelerate initiatives. Bruker is on track for excellent progress in 2021, while we continue to invest in our Project Accelerate 2.0 high-growth, high-margin opportunities and our operational excellence initiative.”

GUIDANCE:

Bruker sees FY2021 EPS of $1.88-$1.93, versus the consensus of $1.89. Sees FY2021 reported revenue growth of 17% to 19%.

For earnings history and earnings-related data on Bruker (BRKR) click here.